NO306257B1 - 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav - Google Patents

11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Info

Publication number
NO306257B1
NO306257B1 NO963427A NO963427A NO306257B1 NO 306257 B1 NO306257 B1 NO 306257B1 NO 963427 A NO963427 A NO 963427A NO 963427 A NO963427 A NO 963427A NO 306257 B1 NO306257 B1 NO 306257B1
Authority
NO
Norway
Prior art keywords
ostra
pharmaceutical composition
substituted phenyl
diene derivatives
diene
Prior art date
Application number
NO963427A
Other languages
English (en)
Other versions
NO963427D0 (no
NO963427L (no
Inventor
Ronald Gebhard
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8220570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO306257(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO963427D0 publication Critical patent/NO963427D0/no
Publication of NO963427L publication Critical patent/NO963427L/no
Publication of NO306257B1 publication Critical patent/NO306257B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO963427A 1995-08-17 1996-08-16 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav NO306257B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP95202229 1995-08-17

Publications (3)

Publication Number Publication Date
NO963427D0 NO963427D0 (no) 1996-08-16
NO963427L NO963427L (no) 1997-02-18
NO306257B1 true NO306257B1 (no) 1999-10-11

Family

ID=8220570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963427A NO306257B1 (no) 1995-08-17 1996-08-16 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav

Country Status (26)

Country Link
US (1) US6011025A (no)
EP (1) EP0763541B1 (no)
JP (1) JP3977462B2 (no)
KR (1) KR100445376B1 (no)
CN (1) CN1129602C (no)
AR (1) AR003982A1 (no)
AT (1) ATE182596T1 (no)
AU (1) AU711369B2 (no)
BR (1) BR9603429A (no)
CA (1) CA2182771C (no)
CZ (1) CZ287740B6 (no)
DE (1) DE69603425T2 (no)
DK (1) DK0763541T3 (no)
ES (1) ES2137625T3 (no)
GR (1) GR3031116T3 (no)
HK (1) HK1002010A1 (no)
HU (1) HU229023B1 (no)
IL (1) IL118974A (no)
NO (1) NO306257B1 (no)
NZ (1) NZ299181A (no)
PL (1) PL183468B1 (no)
RU (1) RU2135514C1 (no)
SG (1) SG52834A1 (no)
TR (1) TR199600664A2 (no)
TW (1) TW464654B (no)
ZA (1) ZA966555B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
EP1726307A3 (en) * 1997-10-06 2007-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
JP2001518509A (ja) 1997-10-06 2001-10-16 ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ グルココルチコイド関連機能不全に関連した精神病の処置のための方法。
WO1999059596A1 (en) 1998-05-15 1999-11-25 The Board Of Trustees Of Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
DE60004377T2 (de) * 1999-04-06 2004-06-09 Akzo Nobel N.V. Oral wirksame 7-alpha-alkyl androgene
JP4499357B2 (ja) * 2001-02-14 2010-07-07 カロ・バイオ・アー・ベー 糖質コルチコイド受容体調節剤
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
PL206687B1 (pl) * 2001-10-26 2010-09-30 Organon Nv Zastosowanie (11ß, 17ß)-11-(1,3-benzodioksol-5-ilo)-17-hydroksy-17-(1-propynylo)-estra-4,9-dien-3-onu do wytwarzania leku do leczenia uogólnionych zaburzeń depresyjnych
EP1453495A2 (en) 2001-11-23 2004-09-08 Akzo Nobel N.V. Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
CA2504751C (en) * 2002-11-05 2013-02-05 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
WO2004069202A2 (en) * 2003-02-04 2004-08-19 Corcept Therapeutics, Inc Antiglucocorticoids for the treatment of postpartum psychosis
TW200820977A (en) 2006-08-08 2008-05-16 Organon Nv Use of glucocorticoid receptor antagonists for treatment of infectious conditions
US8658128B2 (en) * 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2701744A4 (en) * 2011-03-23 2014-08-20 Pop Test Cortisol Llc COMBINATION THERAPY
WO2012135274A1 (en) 2011-03-31 2012-10-04 Pop Test Cortisol Llc Prevention of infection
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3643355A1 (en) 2014-06-03 2020-04-29 Pop Test Abuse Deterrent Technology LLC Drug device configured for wireless communication
CA2977591A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
MX2017012068A (es) 2015-03-23 2018-06-28 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos.
SG11201707525TA (en) 2015-03-30 2017-10-30 Corcept Therapeutics Inc Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
US9598459B2 (en) * 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
EP3400233A4 (en) * 2015-08-03 2020-02-26 Pop Test Oncology LLC PHARMACEUTICAL COMPOSITIONS AND METHODS
WO2017027851A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CA3009525A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
ES2861524T3 (es) 2016-01-19 2021-10-06 Corcept Therapeutics Inc Diagnóstico diferencial del Síndrome de Cushing Ectópico
EP3851444A1 (en) * 2016-10-07 2021-07-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3717169A1 (de) * 1987-05-19 1988-12-01 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0712311B1 (en) * 1993-08-04 1998-10-07 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
DK0683172T3 (da) * 1994-05-19 1998-03-30 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnanderivater

Also Published As

Publication number Publication date
AU6211996A (en) 1997-02-20
DE69603425T2 (de) 2000-01-20
HU9602269D0 (en) 1996-10-28
KR100445376B1 (ko) 2004-11-08
NO963427D0 (no) 1996-08-16
SG52834A1 (en) 1998-09-28
NZ299181A (en) 1997-09-22
EP0763541B1 (en) 1999-07-28
KR970010784A (ko) 1997-03-27
CZ238696A3 (en) 1997-05-14
ES2137625T3 (es) 1999-12-16
IL118974A0 (en) 1996-10-31
RU2135514C1 (ru) 1999-08-27
EP0763541A1 (en) 1997-03-19
JPH09104696A (ja) 1997-04-22
CA2182771C (en) 2007-04-24
JP3977462B2 (ja) 2007-09-19
HK1002010A1 (en) 1998-07-24
CN1129602C (zh) 2003-12-03
HUP9602269A2 (en) 1997-04-28
PL315733A1 (en) 1997-03-03
NO963427L (no) 1997-02-18
AR003982A1 (es) 1998-09-30
HU229023B1 (en) 2013-07-29
PL183468B1 (pl) 2002-06-28
ATE182596T1 (de) 1999-08-15
BR9603429A (pt) 1998-05-12
DK0763541T3 (da) 2000-02-28
CN1147520A (zh) 1997-04-16
US6011025A (en) 2000-01-04
ZA966555B (en) 1997-02-19
MX9603476A (es) 1997-07-31
TW464654B (en) 2001-11-21
HUP9602269A3 (en) 1997-12-29
TR199600664A2 (tr) 1997-03-21
GR3031116T3 (en) 1999-12-31
CA2182771A1 (en) 1997-02-18
AU711369B2 (en) 1999-10-14
CZ287740B6 (en) 2001-01-17
DE69603425D1 (de) 1999-09-02
IL118974A (en) 2001-09-13

Similar Documents

Publication Publication Date Title
NO306257B1 (no) 11-(substituert fenyl)-östra-4,9-dien-derivater, farmasöytisk preparat og anvendelse derav
NO973612D0 (no) Nytt farmasöytisk preparat
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO306401B1 (no) Oksazolidindionderivater, farmasöytisk preparat inneholdende slike derivater, og deres anvendelse
DE69513671D1 (de) Arzneimittel
NO20021172L (no) Farmasöytisk sammensetning
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
ATE367150T1 (de) Arzneimittel
NO996372L (no) Fast farmasøytisk preparat inneholdende benzofuanderivater
NO308533B1 (no) Heteroarylaminer, anvendelse derav og farmasøytisk preparat
NO963032L (no) Oralt preparat
NO20005399L (no) Farmasöytisk preparat
NO307092B1 (no) Sordaridin-derivater, anvendelse derav og farmasoeytisk blanding
NO20011157D0 (no) Benzenderivater og farmasøytisk anvendelse derav
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
NO973610D0 (no) Nytt farmasöytisk preparat
LV11727A (lv) Farmaceitiska kompozicija
ID18698A (id) Komposisi farmasi
FI973280A (fi) Farmaseuttinen koostumus
EE9800209A (et) Antiglükokortikoidne ravimaine
FI951155A (fi) Farmaseuttinen valmiste
NO20000066D0 (no) 6-pyrrolidin-2-ylpyrindin-derivater, deres fremstilling og deres farmasoeytiske anvendelse
NO982549D0 (no) 5-naftalen-1-yl-1,3-dioksan-derivater, fremstilling og terapeutisk anvendelse derav
ITMI962628A0 (it) Composizione farmaceutica

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees